Production (Stage)
Acrivon Therapeutics, Inc.
ACRV
$1.17
$0.021.74%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -1.20% | 0.76% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -13.19% | -0.74% | |||
| Operating Income | 13.19% | 0.74% | |||
| Income Before Tax | 13.80% | -1.74% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 13.80% | -1.74% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 13.80% | -1.74% | |||
| EBIT | 13.19% | 0.74% | |||
| EBITDA | 13.39% | 0.96% | |||
| EPS Basic | 14.04% | -1.38% | |||
| Normalized Basic EPS | 17.30% | -5.35% | |||
| EPS Diluted | 14.04% | -1.38% | |||
| Normalized Diluted EPS | 17.30% | -5.35% | |||
| Average Basic Shares Outstanding | 0.28% | 0.36% | |||
| Average Diluted Shares Outstanding | 0.28% | 0.36% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||